Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status

Petit, Karina; Biard, Jean-François

doi:10.2174/1871520611313040010

Cited by 39 publications

(18 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there is an urgent need to discover lead compounds for development of novel anti-glioma drugs. Marine-derived natural products are important sources for discovery of new anticancer drug leads (Newman and Cragg, 2014;Petit and Biard, 2013;Schumacher et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis

Anjum

Song

et al. 2017

Phytochemistry

View full text Add to dashboard Cite

Two cyclodepsipeptides and a known cyclodepsipeptide valinomycin were isolated from a culture of the marine actinomycete Streptomyces sp. P11-23B. Their structures were established based on NMR, HRESIMS, and MS-MS spectroscopic interpretation as well as by chemical degradation. Both streptodepsipeptides P11A and P11B inhibited proliferation of different glioma cell lines, with IC values ranging from 0.1 μM to 1.4 μM. Streptodepsipeptide P11A was found to block the cell cycle at the G/G phase and induce apoptosis in glioma cells. Further investigation demonstrated that streptodepsipeptide P11A downregulated expression of HK2, PFKFB3, PKM2, GLS, and FASN, important tumor metabolic enzymes. Data from this study suggested that targeting multiple tumor metabolic regulators might be one anti-glioma mechanism of streptodepsipeptide P11A. A possible mechanism for this class of streptodepsipeptides is reported herein.

show abstract

Section: Introductionmentioning

confidence: 99%

Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis

Anjum

Song

et al. 2017

Phytochemistry

View full text Add to dashboard Cite

show abstract

“…From this perspective, there are two papers, one in this journal in 2010 [97], and a very recent and truly comprehensive compilation of clinical trials of a large number of marine-related drugs and drug candidates [98], that could be considered to have partially covered the topic from a marine source perspective. In these two papers, however, a significant number of the agents discussed are no longer in clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development

2014

View full text Add to dashboard Cite

The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, to date, only Cytarabine, Yondelis® (ET743), Eribulin (a synthetic derivative based on the structure of halichondrin B), and the dolastatin 10 derivative, monomethylauristatin E (MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris®). In this review, we show the compounds derived from marine sources that are currently in clinical trials against cancer. We have included brief discussions of the approved agents, where they are in trials to extend their initial approved activity (a common practice once an agent is approved), and have also included an extensive discussion of the use of auristatin derivatives as warheads, plus an area that has rarely been covered, the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies.

show abstract

“…Apart from this, it also disrupts the vasculature by depolymerizing tubulin in Human umbilical vein endothelial cells and is more potent than colchicine or vincristine [72]. It has been tested at Phase I and II randomized trials comparing docetaxel to plinabulin plus docetaxel in patients with advanced Non-small cell lung cancer (NSCLC) who have failed an initial therapy, and the combination has demonstrated marked antitumour activity along with an acceptable safety profile [73].…”

Section: Plinabulin Npi-2358 Kpu-2mentioning

confidence: 99%

Marine Pharmaceuticals: A New Wave of Anti-angiogenic Drugs

Chaugule¹,

Indap²

2018

J Oceanogr Mar Res

View full text Add to dashboard Cite

Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status

Cited by 39 publications

References 167 publications

Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis

Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development

Marine Pharmaceuticals: A New Wave of Anti-angiogenic Drugs

Contact Info

Product

Resources

About